Clinical trials: Degenerative Disorder
- Condition Degenerative Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3
- Trial name
- NCT02960893
- Testing
- Troriluzole
- Where
- 18 sites in United States
- Volunteers
- 141 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Macular Degeneration
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye.
- Trial name
- NCT00658619
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- Allergan
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting…
- Trial name
- NCT04480463
- Testing
- SCD411, Aflibercept
- Where
- 130 sites in United States, Australia and 12 more
- Volunteers
- 576 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Macular Degeneration
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW1 (NCT00509795)
- Testing
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 188 sites in United States, Canada
- Volunteers
- 1,217 people
- Sponsor
- Regeneron Pharmaceuticals
Friedreich Ataxia
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
The purpose of this study is to evaluate the efficacy of TAK-831 versus placebo on upper extremity (arm and hands) motor function and manual dexterity.
- Trial name
- NCT03214588
- Testing
- TAK-831
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neurocrine Biosciences
Neovascular Age-Related Macular Degeneration
Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of…
- Trial name
- NCT02507388
- Testing
- Brolucizumab 3 mg/50 μL, Brolucizumab 6 mg/50 μL
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Joint Diseases
28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study
The study is designed to evaluate artificial hips with a 28 mm ceramic head and a ceramic liner to determine whether they perform as well as artificial hips with a 28 mm ceramic head and a polyethylene liner.
- Trial name
- NCT00208507
- Testing
- 28 mm ceramic head on ceramic acetabular liner., 28 mm ceramic head on polyethylene liner
- Where
- 2 sites in United States
- Volunteers
- 264 people
- Sponsor
- DePuy Orthopaedics
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Troriluzole in Adult Participants With Spinocerebellar Ataxia
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3
- Trial name
- NCT03701399
- Testing
- troriluzole
- Where
- 23 sites in United States, China
- Volunteers
- 299 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Macular Degeneration
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion…
- Trial name
- NCT00239928
- Testing
- pegaptanib sodium
- Where
- 12 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Macular Degeneration
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
- Trial name
- CEDAR (NCT02462928)
- Testing
- Abicipar Pegol, Ranibizumab
- Where
- 151 sites in United States, Argentina and 15 more
- Volunteers
- 939 people
- Sponsor
- Allergan
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04047472
- Testing
- Brolucizumab 6mg, Aflibercept 2 mg
- Where
- 30 sites in China
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
- Trial name
- COBALT (NCT01903720)
- Testing
- dexamethasone implant
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Allergan
Macular Edema, Macular Degeneration
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
The study was designed to assess the efficacy and safety of Lucentis® (ranibizumab 0.5 mg) in diabetic patients presenting with reduced visual acuity due to diabetic macular edema and evaluating spacing out of follow-up after…
- Conditions
- Macular Edema, Macular Degeneration, Diabetes
- Trial name
- CONSTELLATION (NCT02032173)
- Testing
- Ranibizumab 0.5mg
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in…
- Trial name
- STAIRWAY (NCT03038880)
- Testing
- Faricimab, Ranibizumab
- Where
- 25 sites in United States
- Volunteers
- 76 people
- Sponsor
- Hoffmann-La Roche